

UK Genetic Testing Network

NHS Directory of Genetic Testing

**A list of diseases for which tests are offered by
UK Genetic Testing Network Laboratories**

Contents

Introduction	page 3
Structure of the Directory	page 5
Section 1: Listing of those diseases for which tests are available from UKGTN laboratories	page 6
Section 2: New tests for commissioning cycle 2008/09	page 36
Section 3: Approved tests that are currently not available from UKGTN laboratories	page 39

NHS Directory of Genetic Testing available from UKGTN laboratories

Introduction

The UK Genetic Testing Network (<http://www.ukgtn.nhs.uk>) aims to support genetic tests for patients and their families through promoting high quality, equitable, and appropriately validated laboratory tests in the diagnosis and management of inherited genetic disorders. It provides co-ordination of the evaluation and provision of these laboratory services, and supports their commissioning and prioritisation, an approach that is strongly supported by the Department of Health.

Assessing the clinical validity and utility of proposals for new tests to be offered as part of the UKGTN

A core function of the UKGTN is the clinical and scientific evaluation of proposed new genetic tests for adoption as mainstream NHS services. In the context of the UKGTN a genetic test is defined, for this Directory listing, as a test for germ line disorders where nucleic acid is the analyte (i.e. testing for a specific genetic disease, through testing for a causative mutation in DNA, usually present from conception). A tool was developed by the UKGTN Steering Group to evaluate these tests, "Proposal form for the evaluation of a genetic test for NHS service: Gene Dossier" (which is available from the UKGTN website at: http://www.ukgtn.nhs.uk/gtn/Information/Services/UKGTN_Forms).

A genetic test is described as a test for a specified population, for a particular disease and defined genetic variants and for a specific purpose. The UKGTN evaluation of a test considers each of these elements. The analytical sensitivity and specificity are determined by the technologies and methodologies used in the laboratory. The gene dossier evaluation process also considers how the technologies and methodologies have been validated in the providing laboratory. The clinical sensitivity and specificity is calculated for the target population where the target population is described by clinical features or family history of clinical features. The utility of the test describes how the management of the patient will be affected by testing. Tests that are recommended by the UKGTN for NHS service are recommended on the basis of the information provided in the gene dossier.

Gene Dossiers are submitted to the UKGTN Gene Dossier working group for initial evaluation against the agreed criteria. The working group makes recommendations to the UKGTN Steering Group. Tests that are accepted by the Steering Group are taken to the autumn meeting of the Department of Health Genetics Commissioning Advisory Group (GenCAG) for the tests to be considered for inclusion in the Directory and for recommendation to commissioners for funding.

The UKGTN will also evaluate Gene Dossiers for tests that are being proposed to be included in a National Commissioning Group - NCG (formerly the National Specialist Commissioning Advisory Group) service and provided by UKGTN laboratories. Services agreed for funding through NCG are highlighted in green in the Directory.

Commissioning the services listed on the NHS Directory of Molecular Genetic Testing

The UKGTN and GenCAG recommend to all UK commissioners and provider organisations that genetic testing for the diseases listed on the Directory should be available to their local populations. This testing is considered to be clinically appropriate when referred by a clinical professional within agreed protocols.

The recommendation to fund and provide new tests that have passed the gene dossier process is for the relevant health authorities in the United Kingdom. In England services accepted by the Gene Dossier process and which require additional NHS funding will be recommended by UKGTN to the Genetics Commissioning Advisory Group for consideration of funding in the commissioning plans between Specialised Commissioning Groups and Primary Care Trusts. Scotland, Northern Ireland and Wales have different commissioning arrangements and therefore the recommendation for new tests is made to the National Services Division Scotland, the Regional Medical Services Consortium and the Health Commission Wales, respectively. It is recognised by the UKGTN that as NHS commissioning remains within local arrangements that inclusion in the Directory does not guarantee funding.

There are a number of other tests that tend to be of low volume and are provided by non-UKGTN specialist laboratories. These laboratories may be NHS specialist laboratories or overseas laboratories. The tests that are provided by these non-UKGTN specialist laboratories have not been evaluated by the Gene Dossier process and therefore are not included in the Directory. Information about these tests can be obtained by contacting one of the Regional Genetics Centres.

Clinical Referral

The ordering of a genetics test is based on the same process of clinical judgement as is exercised in any aspect of patient care, particularly as to whether the result of the test will significantly affect management. Therefore, each new test listed from July 2005 is accompanied by details of associated testing criteria. The UKGTN has developed the concept of Testing Criteria as part of the Gene Dossier application process. Testing Criteria in essence defines the appropriateness of a genetic test referral, and can inform clinicians' decisions about which investigations are suitable for their patients. Further information about testing criteria is available on the UKGTN website at http://www.ukgt.nhs.uk/gtn/Information/Services/Testing_Criteria. Each of the tests offered may have different clinical uses even in individual families with the same disorder. Usually a mutation has to be detected in an affected family member before specific testing can be offered to the rest of the family. As well as using the listed testing criteria for a condition, further advice regarding the appropriateness of testing in individual cases can be sought from the Regional Genetic Centres.

Monitoring and development of the Directory

The Directory is a regularly updated document with each version identifying those diseases and tests recommended as NHS services. The UKGTN will continue to work with laboratories and clinicians to ensure that the range of tests offered within the Directory continue to meet the criteria for validity and utility.

Structure of the UKGTN Directory of Genetic Testing – Version 5

The directory consists of two columns. The first column lists the name of the disease and where available the symbol and a six-digit number. The name, symbol and the number have been taken from the OMIM (Online Mendelian Inheritance in Man) database (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM>). The second column contains the Human Gene Nomenclature Committee (<http://www.gene.ucl.ac.uk/nomenclature/>) name of the gene and where available the OMIM number of the gene(s) for which Network laboratories provide tests for each disease. The OMIM numbers have been provided so that information about the clinical features of the disease and the characteristics of the gene and its mutations may be accessed through the OMIM database.

Section one

Tests that are currently available from UKGTN laboratories.

Also listed on the UKGTN online database

Included in Section 1 are a number of inherited metabolic diseases (IMD). In many clinical situations, biochemical (metabolite or enzyme) analysis or other types of test may be preferred rather than genetic analysis. However, in certain situations, genetic testing may be the best or only option for a family. Examples where this may be the case include a lack of appropriate material for biochemical tests or invalidation of the biochemical test, e.g. blood transfusion. The test is therefore available as a service in these circumstances. The clinical and laboratory experts or the IMD services are the appropriate gatekeepers for these referrals.

Section two

Testing that has recently been assessed through the UKGTN Gene Dossier process and has been accepted by GenCAG for NHS service from the start of the current year (2008/09).

These tests may not be available initially as the laboratory could be in the process of starting up testing in order for it to be available as a full NHS service.

Tests will only be listed on the UKGTN online database once the test is available for full NHS service.

Section three

Approved tests that are currently not available from any UKGTN laboratories but may be available from laboratories out with the UKGTN. This section is included as these tests should be considered in local funding discussions between UKGTN laboratories, NHS Trusts and commissioners as they have been previously evaluated and accepted for inclusion in the Directory but are currently not offered by a UKGTN laboratory.

Not listed on the UKGTN online database as the database only shows services from UKGTN laboratories.

Additional information

The tests listed in this Directory have been recommended by the UKGTN Steering Group to GenCAG for NHS service and have subsequently been adopted by GenCAG. However there are tests that are provided by UKGTN laboratories as routine NHS provision but which are funded outside the normal NHS commissioning processes and these tests are listed separately on the UKGTN website. In addition further information on the progress of Gene Dossiers is available on the UKGTN website.

Section 1

This section contains a list of approved diseases and the associated tests that are currently being offered by UKGTN laboratories.

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
ACANTHOSIS NIGRICANS; AN	100600	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
ACHONDROPLASIA; ACH	100800	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
ACYL-CoA DEHYDROGENASE, LONG-CHAIN, DEFICIENCY OF	201460	HYDROXYACYL-COENZYME A DEHYDROGENASE/3-KETOACYL-COENZYME A THIOLASE/ENOYL-COENZYME A HYDRATASE (TRIFUNCTIONAL PROTEIN), ALPHA SUBUNIT; HADHA	600890
ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF	201450	ACYL-COENZYME A DEHYDROGENASE, C-4 TO C-12 STRAIGHT CHAIN; ACADM	607008
ADENOMATOUS POLYPOSIS OF THE COLON; APC	175100	ADENOMATOSIS POLYPOSIS COLI; APC	175100
ADENOSINE MONOPHOSPHATE DEAMINASE 1; AMPD1	102770	ADENOSINE MONOPHOSPHATE DEAMINASE 1 (ISOFORM M); AMPD1	102770
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY	201910	CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2	201910
ADRENAL HYPOPLASIA, CONGENITAL; AHC	300200	nuclear receptor subfamily 0, group B, member 1; NR0B1	300473
ADRENOLEUKODYSTROPHY; ALD	300100	ATP-BINDING CASSETTE, SUB-FAMILY D (ALD), MEMBER 1; ABCD1	300371
ALAGILLE SYNDROME; AGS	118450	JAGGED 1 (ALAGILLE SYNDROME); JAG1	601920
ALBRIGHT HEREDITARY OSTEODYSTROPHY; AHO	103580	GNAS COMPLEX LOCUS; GNAS	139320
ALEXANDER DISEASE	203450	GLIAL FIBRILLARY ACIDIC PROTEIN; GFAP	137780
ALLAN-HERNDON-DUDLEY SYNDROME; AHDS	300523	solute carrier family 16, member 2 (monocarboxylic acid transporter 8); SLC16A2	300095

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS	203700	POLYMERASE (DNA DIRECTED), GAMMA; POLG	174763
ALPORT SYNDROME, X-LINKED; ATS	301050	COLLAGEN, TYPE IV, ALPHA 5 (ALPORT SYNDROME); COL4A5	303630
ALSTROM SYNDROME; ALMS	203800	ALSTROM SYNDROME 1; ALMS1	606844
ALZHEIMER DISEASE; AD	104300	PRESENILIN 1 (ALZHEIMER DISEASE 3); PSEN1	104311
AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1	105400	SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC LATERAL SCLEROSIS 1 (ADULT)); SOD1	147450
ANDROGEN INSENSITIVITY SYNDROME; AIS	300068	ANDROGEN RECEPTOR (DIHYDROTESTOSTERONE RECEPTOR; TESTICULAR FEMINIZATION; SPINAL AND BULBAR MUSCULAR ATROPHY; KENNEDY DISEASE); AR	313700
ANGELMAN SYNDROME; AS	105830	NONIMPRINTED GENE IN PRADER-WILLI SYNDROME/ANGELMAN SYNDROME CHROMOSOME REGION 2	608146
		SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE N; SNRPN	182279
		UBIQUITIN PROTEIN LIGASE E3A (HUMAN PAPILLOMA VIRUS E6-ASSOCIATED PROTEIN, ANGELMAN SYNDROME); UBE3A	601623
ANIRIDIA; AN1	106200	PAIRED BOX 6; PAX6	607108
ANTLEY-BIXLER SYNDROME; ABS	207410	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943
		P450 (CYTOCHROME) OXIDOREDUCTASE; POR	124015

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
APERT SYNDROME	101200	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943
APOLIPOPROTEIN E; APOE	107741	APOLIPOPROTEIN E; APOE	107741
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS	601859	Fas (TNF receptor superfamily, member 6); FAS	134637
AUTOIMMUNE POLYENDOCRINOPATHY SYNDROME, TYPE I	240300	autoimmune regulator; AIRE	607358
AUTONOMIC CONTROL, CONGENITAL FAILURE OF	209880	PAIRED-LIKE HOMEODOMAIN 2B; PHOX2B	603851
BARTH SYNDROME; BTHS	302060	TAFAZZIN (CARDIOMYOPATHY, DILATED 3A (X-LINKED); ENDOCARDIAL FIBROELASTOSIS 2; BARTH SYNDROME); TAZ	300394
BASAL CELL NEVUS SYNDROME; BCNS	109400	patched homolog 1 (Drosophila); PTCH1	601309
BASAL GANGLIA DISEASE, ADULT-ONSET	606159	FERRITIN, LIGHT POLYPEPTIDE; FTL	134790
BECKWITH-WIEDEMANN SYNDROME; BWS	130650	CYCLIN-DEPENDENT KINASE INHIBITOR 1C (P57, KIP2); CDKN1C	600856
BETA THALASSEMIA, DOMINANT INCLUSION BODY TYPE	603902	HEMOGLOBIN, BETA; HBB	141900
BRACHYDACTYLY, TYPE B1; BDB1	113000	RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 2; ROR2	602337
BRACHYDACTYLY, TYPE D; BDD	113200	homeobox D13; HOXD13	142989
BRACHYDACTYLY, TYPE E; BDE	113300	homeobox D13; HOXD13	142989
BRANCHIOOTORENAL DYSPLASIA	113650	EYES ABSENT HOMOLOG 1 (DROSOPHILA); EYA1	601653
BREAST CANCER	114480	BREAST CANCER 1, EARLY ONSET; BRCA1	113705
		BREAST CANCER 2, EARLY ONSET; BRCA2	600185

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
BRUGADA SYNDROME	601144	sodium channel, voltage-gated, type V, alpha subunit; SCN5A	600163
BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK	300300	BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK	300300
BULLOUS ERYTHRODERMA ICHTHYOSIFORMIS CONGENITA OF BROCQ	113800	KERATIN 1 (EPIDERMOLYTIC HYPERKERATOSIS); KRT1	139350
		KERATIN 10 (EPIDERMOLYTIC HYPERKERATOSIS; KERATOSIS PALMARIS ET PLANTARIS); KRT10	148080
CANAVAN DISEASE	271900	aspartoacylase (Canavan disease); ASPA	608034
CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	237300	CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO	237300
CARDIOMYOPATHY, DILATED, 1A; CMD1A	115200	LAMIN A/C; LMNA	150330
		MYOSIN BINDING PROTEIN C, CARDIAC; MYBPC3	600958
		myosin, heavy chain 7, cardiac muscle, beta; MYH7	160760
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 2; CMH2	115195	troponin T type 2 (cardiac); TNNT2	191045
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4; CMH4	115197	MYOSIN BINDING PROTEIN C, CARDIAC; MYBPC3	600958
CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC; CMH	192600	mitochondrially encoded tRNA leucine 1 (UUA/G); MT-TL1	590050
		MYOSIN BINDING PROTEIN C, CARDIAC; MYBPC3	600958
		myosin, heavy chain 7, cardiac muscle, beta; MYH7	160760
		troponin I type 3 (cardiac); TNNI3	191044
		troponin T type 2 (cardiac); TNNT2	191045
CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET	255110	CARNITINE PALMITOYLTRANSFERASE II; CPT2	600650
CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY; CADASIL	125310	NOTCH HOMOLOG 3 (DROSOPHILA); NOTCH3	600276

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
CEROID LIPOFUSCINOSIS, NEURONAL 1, INFANTILE; CLN1	256730	PALMITOYL-PROTEIN THIOESTERASE 1 (CEROID-LIPOFUSCINOSIS, NEURONAL 1, INFANTILE); PPT1	600722
CEROID LIPOFUSCINOSIS, NEURONAL 2, LATE INFANTILE; CLN2	204500	TRIPEPTIDYL PEPTIDASE I; TPP1	607998
CEROID LIPOFUSCINOSIS, NEURONAL 3, JUVENILE; CLN3	204200	CEROID-LIPOFUSCINOSIS, NEURONAL 3, JUVENILE (BATTEN, SPIELMEYER-VOGT DISEASE); CLN3	607042
CEROID LIPOFUSCINOSIS, NEURONAL 6; CLN6	601708	CEROID-LIPOFUSCINOSIS, NEURONAL 3, JUVENILE (BATTEN, SPIELMEYER-VOGT DISEASE); CLN3	607042
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1	605588	LAMIN A/C; LMNA	150330
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A	118220	PERIPHERAL MYELIN PROTEIN 22; PMP22	601097
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B	118200	MYELIN PROTEIN ZERO (CHARCOT-MARIE-TOOTH NEUROPATHY 1B); MPZ	159440
CHARCOT-MARIE-TOOTH DISEASE, X-LINKED, 1; CMTX1	302800	gap junction protein, beta 1, 32kDa; GJB1	304040
CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1	302950	EMOPAMIL BINDING PROTEIN (STEROL ISOMERASE); EBP	300205
		PEROXISOMAL BIOGENESIS FACTOR 7; PEX7	601757
CHOROIDEREMIA; CHM	303100	CHOROIDEREMIA (RAB ESCORT PROTEIN 1); CHM	300390
CLEIDOCRANIAL DYSPLASIA; CCD	119600	RUNT-RELATED TRANSCRIPTION FACTOR 2; RUNX2	600211
COAGULATION FACTOR II; F2	176930	COAGULATION FACTOR II (THROMBIN); F2	176930
COFFIN-LOWRY SYNDROME; CLS	303600	RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; RPS6KA3	300075
COLORECTAL ADENOMATOUS POLYPOSIS, AUTOSOMAL RECESSIVE	608456	MUTY HOMOLOG (E. COLI); MUTYH	604933

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS; HNPCC	114500	Microsatellite instability; MSI	
		mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli).; MLH1	120436
		MUTS HOMOLOG 2, COLON CANCER, NONPOLYPOSIS TYPE 1 (E. COLI); MSH2	120435
		MUTS HOMOLOG 6 (E. COLI); MSH6	600678
CONGENITAL MUSCULAR DYSTROPHY WITH GLYCOSYLATION DEFECTS		Fukuyama type congenital muscular dystrophy (fukutin); FCMD	607440
		like-glycosyltransferase; LARGE	603590
		protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase; POMGNT1	606822
		protein-O-mannosyltransferase 1; POMT1	607423
		protein-O-mannosyltransferase 2; POMT2	607439
COPROPORPHYRIA	121300	coproporphyrinogen oxidase; CPOX	121300
COSTELLO SYNDROME	218040	v-Ha-ras Harvey rat sarcoma viral oncogene homolog; HRAS	190020
COWDEN DISEASE; CD	158350	PHOSPHATASE AND TENSIN HOMOLOG (MUTATED IN MULTIPLE ADVANCED CANCERS 1); PTEN	601728
CRANIOFRONTONASAL SYNDROME; CFNS	304110	ephrin-B1; EFN1	300035
CRIGLER-NAJJAR SYNDROME	218800	UDP glucuronosyltransferase 1 family, polypeptide A1; UGT1A1	191740
CROUZON SYNDROME	123500	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME); FGFR1	136350
		FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
CROUZON SYNDROME	123500	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
		TWIST HOMOLOG 1 (ACROCEPHALOSYNDACTYLY 3; SAETHRE-CHOTZEN SYNDROME) (DROSOPHILA); TWIST1	601622
CUTIS GYRATA SYNDROME OF BEARE AND STEVENSON	123790	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME); FGFR1	136350
		FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943
		FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
		TWIST HOMOLOG 1 (ACROCEPHALOSYNDACTYLY 3; SAETHRE-CHOTZEN SYNDROME) (DROSOPHILA); TWIST1	601622
CYSTIC FIBROSIS; CF	219700	cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7); CFTR	602421
CYSTINOSIS, ADULT NONNEPHROPATHIC	219750	CYSTINOSIS, NEPHROPATHIC; CTNS	606272
CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE	219900	CYSTINOSIS, NEPHROPATHIC; CTNS	606272
CYSTINOSIS, NEPHROPATHIC; CTNS	219800	CYSTINOSIS, NEPHROPATHIC; CTNS	606272
DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA	125370	atrophin 1; ATN1	607462

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
DIABETES MELLITUS, PERMANENT NEONATAL; PNDM	606176	POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 11; KCNJ11	600937
DIABETES MELLITUS, TRANSIENT NEONATAL	601410	POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 11; KCNJ11	600937
DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED	520000	mitochondrially encoded tRNA leucine 1 (UUA/G); MT-TL1	590050
DILATED CARDIOMYOPATHY; DCM		myosin, heavy chain 7, cardiac muscle, beta; MYH7	160760
		troponin T type 2 (cardiac); TNNT2	191045
DYSTONIA, FAMILIAL, WITH VISUAL FAILURE AND STRIATAL LUCENCIES	500001	mitochondrially encoded NADH dehydrogenase 6; MT-ND6	516006
DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION	128230	GTP CYCLOHYDROLASE 1 (DOPA-RESPONSIVE DYSTONIA); GCH1	600225
DYSTROPHIA MYOTONICA 1	160900	DYSTROPHIA MYOTONICA-PROTEIN KINASE; DMPK	605377
DYSTROPHIA MYOTONICA 2; DM2	602668	CCHC-type zinc finger, nucleic acid binding protein; CNBP	116955
ECTODERMAL DYSPLASIA 1, ANHIDROTIC; ED1	305100	ECTODYSPLASIN A; EDA	300451
ECTODERMAL DYSPLASIA 2, HIDROTIC; ED2	129500	gap junction protein, beta 6; GJB6	604418
ECTODERMAL DYSPLASIA 3, ANHIDROTIC; ED3	129490	ECTODYSPLASIN A RECEPTOR; EDAR	604095
ECTODERMAL DYSPLASIA, ANHIDROTIC	224900	ECTODYSPLASIN A RECEPTOR; EDAR	604095
EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT	130050	collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); COL3A1	120180
EMERY-DREIFUSS MUSCULAR DYSTROPHY, AUTOSOMAL DOMINANT; EDMD2	181350	LAMIN A/C; LMNA	150330
EMERY-DREIFUSS MUSCULAR DYSTROPHY, X-LINKED; EDMD	310300	EMERIN (EMERY-DREIFUSS MUSCULAR DYSTROPHY); EMD	300384

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
EPIDERMOLYSIS BULLOSA HERPETIFORMIS, DOWLING-MEARA TYPE	131760	KERATIN 14 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA, KOEBNER); KRT14	148066
		KERATIN 5 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA/KOBNER/WEBER-COCKAYNE TYPES); KRT5	148040
EPIDERMOLYSIS BULLOSA OF HANDS AND FEET	131800	KERATIN 14 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA, KOEBNER); KRT14	148066
		KERATIN 5 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA/KOBNER/WEBER-COCKAYNE TYPES); KRT5	148040
EPIDERMOLYSIS BULLOSA SIMPLEX, KOEBNER TYPE; EBS2	131900	KERATIN 14 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA, KOEBNER); KRT14	148066
		KERATIN 5 (EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA/KOBNER/WEBER-COCKAYNE TYPES); KRT5	148040
EPILEPSY, MYOCLONIC, X-LINKED, WITH MENTAL RETARDATION AND SPASTICITY	300432	ARISTALESS RELATED HOMEobox; ARX	300382
EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS	226980	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3; EIF2AK3	604032
EXTRAPYRAMIDAL DISORDER, PROGRESSIVE, WITH PRIMARY HYPOGONADISM AND ALOPECIA	601164	TYROSINE HYDROXYLASE; TH	191290
FABRY DISEASE	301500	GALACTOSIDASE, ALPHA; GLA	301500
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1A; FSHMD1A	158900	FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1A; FSHMD1A	158900
FACTOR V DEFICIENCY	227400	PROTEIN C (INACTIVATOR OF COAGULATION FACTORS VA AND VIIIA); PROC	176860
FANCONI ANEMIA; FA		FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA	607139

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
FANCONI ANEMIA; FA		FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC	227645
FRAGILE SITE MENTAL RETARDATION 1 GENE; FMR1	309550	FRAGILE X MENTAL RETARDATION 1; FMR1	309550
FRAGILE SITE, FOLIC ACID TYPE, RARE, FRA(X)(q28); FRAXE	309548	AF4/FMR2 family, member 2; AFF2	309548
FRASIER SYNDROME	136680	WILMS TUMOR 1; WT1	607102
FRIEDREICH ATAXIA 1; FRDA	229300	FRATAXIN; FXN	606829
FRONTOMETAPHYSEAL DYSPLASIA; FMD	305620	FILAMIN A, ALPHA (ACTIN BINDING PROTEIN 280); FLNA	300017
FRONTOTEMPORAL DEMENTIA	600274	MICROTUBULE-ASSOCIATED PROTEIN TAU; MAPT	157140
FRUCTOSE INTOLERANCE, HEREDITARY	229600	ALDOLASE B, FRUCTOSE-BISPHOSPHATE; ALDOB	229600
FUNDUS DYSTROPHY, PSEUDOINFLAMMATORY, OF SORSBY; SFD	136900	TIMP metalloproteinase inhibitor 3 (Sorsby fundus dystrophy, pseudo-inflammatory); TIMP3	188826
GALACTOSEMIA	230400	GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE; GALT	606999
GAP JUNCTION PROTEIN, BETA-2; GJB2	121011	gap junction protein, beta 2, 26kDa; GJB2	121011
GASTRIC CANCER	137215	CADHERIN 1, TYPE 1, E-CADHERIN (EPITHELIAL); CDH1	192090
GAUCHER DISEASE, TYPE I	230800	GLUCOSIDASE, BETA; ACID (INCLUDES GLUCOSYLCERAMIDASE); GBA	606463
GAUCHER DISEASE, TYPE II	230900	GLUCOSIDASE, BETA; ACID (INCLUDES GLUCOSYLCERAMIDASE); GBA	606463
GAUCHER DISEASE, TYPE III	231000	GLUCOSIDASE, BETA; ACID (INCLUDES GLUCOSYLCERAMIDASE); GBA	606463
GENETIC IDENTITY		LABORATORY SPECIFIC TEST	
GILBERT SYNDROME	143500	UDP glucuronosyltransferase 1 family, polypeptide A1; UGT1A1	191740

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
GITELMAN SYNDROME; GS	263800	solute carrier family 12 (sodium/chloride transporters), member 3; SLC12A3	600968
GLUCOSE-6-PHOSPHATE DEHYDROGENASE; G6PD	305900	GLUCOSE-6-PHOSPHATE DEHYDROGENASE; G6PD	305900
GLUTARICACIDEMIA I	231670	glutaryl-Coenzyme A dehydrogenase; GCDH	608801
GLYCINE ENCEPHALOPATHY; GCE	605899	aminomethyltransferase; AMT	238310
		glycine dehydrogenase (decarboxylating); GLDC	238300
GLYCOGEN STORAGE DISEASE I	232200	solute carrier family 37 (glucose-6-phosphate transporter), member 4; SLC37A4	602671
GLYCOGEN STORAGE DISEASE Ib	232220	solute carrier family 37 (glucose-6-phosphate transporter), member 4; SLC37A4	602671
GLYCOGEN STORAGE DISEASE Ic GLYCOGEN STORAGE DISEASE Id, INCLUDED	232240	solute carrier family 37 (glucose-6-phosphate transporter), member 4; SLC37A4	602671
GLYCOGEN STORAGE DISEASE III	232400	AMYLO-1, 6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE (GLYCOGEN DEBRANCHING ENZYME, GLYCOGEN STORAGE DISEASE TYPE III); AGL	232400
GLYCOGEN STORAGE DISEASE V	232600	PHOSPHORYLASE, GLYCOGEN; MUSCLE (MCARDLE SYNDROME, GLYCOGEN STORAGE DISEASE TYPE V); PYGM	608455
GONADAL DYSGENESIS, XY FEMALE TYPE; GDXY	306100	SEX DETERMINING REGION Y; SRY	480000
GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS	175700	GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome); GLI3	165240
GTP CYCLOHYDROLASE I DEFICIENCY; GTP	233910	GTP CYCLOHYDROLASE 1 (DOPA-RESPONSIVE DYSTONIA); GCH1	600225
HEMOCHROMATOSIS; HFE	235200	HEMOCHROMATOSIS; HFE	235200
HEMOGLOBIN F, HEREDITARY PERSISTENCE OF, PANCELLULAR	141749	HEMOGLOBIN, BETA; HBB	141900
		HEMOGLOBIN, DELTA; HBD	142000
		HEMOGLOBIN, GAMMA A; HBG1	142200
		HEMOGLOBIN, GAMMA G; HBG2	142250

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
HEMOGLOBIN--VARIANTS FOR WHICH THE CHAIN CARRYING THE MUTATION IS UNKNOWN OR UNCERTAIN	142309	HEMOGLOBIN, ALPHA 1; HBA1	141800
		HEMOGLOBIN, ALPHA 2; HBA2	141850
		HEMOGLOBIN, BETA; HBB	141900
HEMOLYTIC-UREMIC SYNDROME; HUS	235400	COMPLEMENT FACTOR H; CFH	134370
HEMOPHILIA A	306700	COAGULATION FACTOR VIII, PROCOAGULANT COMPONENT (HEMOPHILIA A); F8	306700
HEMOPHILIA B; HEMB	306900	coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B); F9	306900
HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, HETEROCELLULAR, INDIAN TYPE; HPFH2	142335	HEMOGLOBIN, BETA; HBB	141900
		HEMOGLOBIN, DELTA; HBD	142000
		HEMOGLOBIN, GAMMA A; HBG1	142200
		HEMOGLOBIN, GAMMA G; HBG2	142250
HETEROCELLULAR HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN; HPFH	142470	HEMOGLOBIN, BETA; HBB	141900
		HEMOGLOBIN, DELTA; HBD	142000
		HEMOGLOBIN, GAMMA A; HBG1	142200
		HEMOGLOBIN, GAMMA G; HBG2	142250
HETEROTOPIA, PERIVENTRICULAR, X-LINKED DOMINANT	300049	FILAMIN A, ALPHA (ACTIN BINDING PROTEIN 280); FLNA	300017
HIRSCHSPRUNG DISEASE	142623	ret proto-oncogene; RET	164761
HOLT-ORAM SYNDROME; HOS	142900	T-BOX 5; TBX5	601620
HOMOCYSTINURIA	236200	CYSTATHIONINE-BETA-SYNTHASE; CBS	236200
HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE REDUCTASE ACTIVITY	236250	5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH); MTHFR	607093

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
HUNTINGTON DISEASE; HD	143100	HUNTINGTIN (HUNTINGTON DISEASE); HD	143100
HURLER-SCHEIE SYNDROME; HSS	607015	IDURONIDASE, ALPHA-L-; IDUA	252800
HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS	176670	LAMIN A/C; LMNA	150330
HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS	307000	L1 cell adhesion molecule; L1CAM	308840
HYPERALDOSTERONISM, FAMILIAL, TYPE I	103900	CYTOCHROME P450, FAMILY 11, SUBFAMILY B, POLYPEPTIDE 1; CYP11B1	202010
		CYTOCHROME P450, FAMILY 11, SUBFAMILY B, POLYPEPTIDE 2; CYP11B2	124080
HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT	143890	LOW DENSITY LIPOPROTEIN RECEPTOR (FAMILIAL HYPERCHOLESTEROLEMIA); LDLR	606945
HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B	144010	APOLIPOPROTEIN B (INCLUDING AG(X) ANTIGEN); APOB	107730
HYPERINSULINISM, AUTOSOMAL DOMINANT	602485	GLUCOKINASE (HEXOKINASE 4, MATURITY ONSET DIABETES OF THE YOUNG 2); GCK	138079
HYPERINSULINISM-HYPERAMMONEMIA SYNDROME	606762	GLUTAMATE DEHYDROGENASE 1; GLUD1	138130
HYPERKALEMIC PERIODIC PARALYSIS; HYPP	170500	sodium channel, voltage-gated, type IV, alpha subunit; SCN4A	603967
HYPEROXALURIA, PRIMARY, TYPE I	259900	alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine-pyruvate aminotransferase); AGXT	604285
HYPEROXALURIA, PRIMARY, TYPE II	260000	glyoxylate reductase/hydroxypyruvate reductase; GRHPR	604296
HYPERPARATHYROIDISM 2; HRPT2	145001	cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae); CDC73	607393
HYPERPARATHYROIDISM, NEONATAL SEVERE PRIMARY; NSHPT	239200	CALCIUM-SENSING RECEPTOR (HYPOCALCIURIC HYPERCALCEMIA 1, SEVERE NEONATAL HYPERPARATHYROIDISM); CASR	601199

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
HYPERTHYROIDISM, FAMILIAL GESTATIONAL	603373	THYROID STIMULATING HORMONE RECEPTOR; TSHR	603372
HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ	162000	uromodulin (uromucoid, Tamm-Horsfall glycoprotein); UMOD	191845
HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1	145980	CALCIUM-SENSING RECEPTOR (HYPOCALCIURIC HYPERCALCEMIA 1, SEVERE NEONATAL HYPERPARATHYROIDISM); CASR	601199
HYPOCHONDROPLASIA; HCH	146000	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
HYPOKALEMIC PERIODIC PARALYSIS; HOKPP	170400	CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA 1S SUBUNIT; CACNA1S	114208
HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH	146200	CALCIUM-SENSING RECEPTOR (HYPOCALCIURIC HYPERCALCEMIA 1, SEVERE NEONATAL HYPERPARATHYROIDISM); CASR	601199
		GLIAL CELLS MISSING HOMOLOG 2 (DROSOPHILA); GCM2	603716
		PARATHYROID HORMONE; PTH	168450
HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA	146255	GATA BINDING PROTEIN 3; GATA3	131320
HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR	193100	FIBROBLAST GROWTH FACTOR 23; FGF23	605380
		PHOSPHATE REGULATING ENDOPEPTIDASE HOMOLOG, X-LINKED (HYPOPHOSPHATEMIA, VITAMIN D RESISTANT RICKETS); PHEX	307800
ICHTHYOSIS, BULLOUS TYPE	146800	keratin 2 (epidermal ichthyosis bullosa of Siemens); KRT2	600194
ICHTHYOSIS, X-LINKED	308100	STEROID SULFATASE (MICROSOMAL), ISOZYME S; STS	308100

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1	308230	CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome); CD40LG	300386
INCONTINENTIA PIGMENTI; IP	308300	INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B-CELLS, KINASE GAMMA; IKBKG	300248
INFANTILE SPASM SYNDROME, X-LINKED	308350	ARISTALESS RELATED HOMEBOX; ARX	300382
JACKSON-WEISS SYNDROME; JWS	123150	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943
KEARNS-SAYRE SYNDROME; KSS	530000	KEARNS-SAYRE SYNDROME; KSS	530000
		MITOCHONDRIAL GENOME	
KRABBE DISEASE	245200	galactosylceramidase; GALC	606890
LEBER OPTIC ATROPHY	535000	mitochondrially encoded ATP synthase 6; MT-ATP6	516060
		mitochondrially encoded NADH dehydrogenase 1; MT-ND1	516000
		mitochondrially encoded NADH dehydrogenase 4; MT-ND4	516003
		mitochondrially encoded NADH dehydrogenase 6; MT-ND6	516006
LEIGH SYNDROME; LS	256000	mitochondrially encoded ATP synthase 6; MT-ATP6	516060
		mitochondrially encoded NADH dehydrogenase 6; MT-ND6	516006
LERI-WEILL DYSCHONDROSTEOSIS; LWD	127300	SHORT STATURE HOMEBOX; SHOX	312865
LESCH-NYHAN SYNDROME; LNS	300322	HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE 1 (LESCH-NYHAN SYNDROME); HPRT1	308000
LI-FRAUMENI SYNDROME; LFS	151623	TUMOR PROTEIN P53 (LI-FRAUMENI SYNDROME); TP53	191170

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
LIDDLE SYNDROME	177200	sodium channel, nonvoltage-gated 1, beta (Liddle syndrome); SCNN1B	600760
		sodium channel, nonvoltage-gated 1, gamma; SCNN1G	600761
LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2	151660	LAMIN A/C; LMNA	150330
LISSENCEPHALY I; LIS1	607432	PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM IB, ALPHA SUBUNIT 45KDA; PAFAH1B1	601545
LISSENCEPHALY, X-LINKED, WITH AMBIGUOUS GENITALIA; XLAG	300215	ARISTALESS RELATED HOMEBOX; ARX	300382
LISSENCEPHALY, X-LINKED; LISX	300067	DOUBLECORTEX; LISSENCEPHALY, X-LINKED (DOUBLECORTIN); DCX	300121
LONG QT SYNDROME 1; LQT1	192500	POTASSIUM VOLTAGE-GATED CHANNEL, KQT-LIKE SUBFAMILY, MEMBER 1; KCNQ1	607542
LONG QT SYNDROME 3; LQT3	603830	sodium channel, voltage-gated, type V, alpha subunit; SCN5A	600163
LOWE OCULOCEREBRORENAL SYNDROME; OCRL	309000	OCULOCEREBRORENAL SYNDROME OF LOWE; OCRL	309000
LYMPHEDEMA, HEREDITARY, I	153100	FMS-RELATED TYROSINE KINASE 4; FLT4	136352
LYMPHEDEMA-DISTICHIASIS SYNDROME	153400	FORKHEAD BOX C2 (MFH-1, MESENCHYME FORKHEAD 1); FOXC2	602402
LYMPHOPROLIFERATIVE SYNDROME, X-LINKED	308240	LYMPHOPROLIFERATIVE SYNDROME, X-LINKED	308240
MACHADO-JOSEPH DISEASE; MJD	109150	ATAXIN 3; ATXN3	607047
MACROCEPHALY, MULTIPLE LIPOMAS, AND HEMANGIOMATA	153480	PHOSPHATASE AND TENSIN HOMOLOG (MUTATED IN MULTIPLE ADVANCED CANCERS 1); PTEN	601728
MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1	145600	RYANODINE RECEPTOR 1 (SKELETAL); RYR1	180901
MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA	248370	LAMIN A/C; LMNA	150330
MARFAN SYNDROME, TYPE II; MFS2	154705	transforming growth factor, beta receptor II (70/80kDa); TGFBR2	190182

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
MARFAN SYNDROME; MFS	154700	fibrillin 1; FBN1	134797
MATURITY-ONSET DIABETES OF THE YOUNG, TYPE V; MODY5	604284	TRANSCRIPTION FACTOR 2, HEPATIC; LF-B3; VARIANT HEPATIC NUCLEAR FACTOR; TCF2	189907
MATURITY-ONSET DIABETES OF THE YOUNG; MODY	606391	GLUCOKINASE (HEXOKINASE 4, MATURITY ONSET DIABETES OF THE YOUNG 2); GCK	138079
		HEPATOCTE NUCLEAR FACTOR 4, ALPHA; HNF4A	600281
		NEUROGENIC DIFFERENTIATION 1; NEUROD1	601724
		pancreatic and duodenal homeobox 1; PDX1	600733
		TRANSCRIPTION FACTOR 1, HEPATIC; LF-B1, HEPATIC NUCLEAR FACTOR (HNF1), ALBUMIN PROXIMAL FACTOR; TCF1	142410
MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2	603860	uromodulin (uromucoid, Tamm-Horsfall glycoprotein); UMOD	191845
MELANOMA, CUTANEOUS MALIGNANT; CMM	155600	CYCLIN-DEPENDENT KINASE INHIBITOR 2A (MELANOMA, P16, INHIBITS CDK4); CDKN2A	600160
MELNICK-NEEDLES SYNDROME; MNS	309350	FILAMIN A, ALPHA (ACTIN BINDING PROTEIN 280); FLNA	300017
MENKES DISEASE; MENKE	309400	ATPase, Cu ⁺⁺ transporting, alpha polypeptide (Menkes syndrome); ATP7A	300011
MENTAL RETARDATION, X-LINKED 36; MRX36	300430	ARISTALESS RELATED HOMEODOMAIN; ARX	300382
METACHROMATIC LEUKODYSTROPHY	250100	ARYLSULFATASE A; ARSA	607574
MITOCHONDRIAL DISORDERS		LABORATORY SPECIFIC TEST	
MITOCHONDRIAL DNA DEPLETION SYNDROME, HEPATOCEREBRAL FORM MITOCHONDRIAL DNA DEPLETION MYOPATHY, INCLUDED	251880	MITOCHONDRIAL GENOME	
MITOCHONDRIAL MYOPATHY	251900	MITOCHONDRIAL MYOPATHY	251900

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
MITOCHONDRIAL MYOPATHY WITH DIABETES	500002	TRANSFER RNA, MITOCHONDRIAL, GLUTAMIC ACID; MTTE	590025
MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS	540000	mitochondrially encoded tRNA leucine 1 (UUA/G); MT-TL1	590050
MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME; MNGIE	603041	ENDOTHELIAL CELL GROWTH FACTOR 1 (PLATELET-DERIVED); ECGF1	131222
		MITOCHONDRIAL GENOME	
MITOCHONDRIAL-RELATED DEAFNESS		mitochondrially encoded 12S RNA; MT-RNR1	561000
MOWAT-WILSON SYNDROME	235730	zinc finger E-box binding homeobox 2; ZEB2	605802
MUCOPOLYSACCHARIDOSIS TYPE II	309900	IDURONATE 2-SULFATASE (HUNTER SYNDROME); IDS	309900
MUCOPOLYSACCHARIDOSIS TYPE IIIA	252900	N-SULFOGLUCOSAMINE SULFOHYDROLASE (SULFAMIDASE); SGSH	605270
MUCOPOLYSACCHARIDOSIS TYPE IVA	253000	GALACTOSAMINE (N-ACETYL)-6-SULFATE SULFATASE (MORQUIO SYNDROME, MUCOPOLYSACCHARIDOSIS TYPE IVA); GALNS	253000
MUENKE SYNDROME	602849	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
MUIR-TORRE SYNDROME; MTS	158320	mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli).; MLH1	120436
		MUTS HOMOLOG 2, COLON CANCER, NONPOLYPOSIS TYPE 1 (E. COLI); MSH2	120435
MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1	131100	SECRETOGANIN II (CHROMOGANIN C); SCG2	118930
MULTIPLE ENDOCRINE NEOPLASIA, TYPE II; MEN2	171400	ret proto-oncogene; RET	164761
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B	162300	ret proto-oncogene; RET	164761

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
MUSCULAR DYSTROPHY, BECKER TYPE; BMD	300376	DYSTROPHIN (MUSCULAR DYSTROPHY, DUCHENNE AND BECKER TYPES); DMD	300377
MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A	607855	LAMININ, ALPHA 2 (MEROSIN, CONGENITAL MUSCULAR DYSTROPHY); LAMA2	156225
MUSCULAR DYSTROPHY, CONGENITAL, 1C; MDC1C	606612	FUKUTIN RELATED PROTEIN; FKRP	606596
MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD	310200	DYSTROPHIN (MUSCULAR DYSTROPHY, DUCHENNE AND BECKER TYPES); DMD	300377
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B; LGMD1B	159001	LAMIN A/C; LMNA	150330
MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A	253600	FUKUTIN RELATED PROTEIN; FKRP	606596
		LAMIN A/C; LMNA	150330
MutY, E. COLI, HOMOLOG OF; MUTYH	604933	MUTY HOMOLOG (E. COLI); MUTYH	604933
MYASTHENIC SYNDROME, CONGENITAL, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY	608931	cholinergic receptor, nicotinic, epsilon; CHRNE	100725
		receptor-associated protein of the synapse, 43kD; RAPSN	601592
MYASTHENIC SYNDROME, CONGENITAL, ASSOCIATED WITH EPISODIC APNEA	254210	CHOLINE ACETYLTRANSFERASE; CHAT	118490
MYASTHENIC SYNDROME, CONGENITAL, FAST-CHANNEL	608930	cholinergic receptor, nicotinic, alpha 1 (muscle); CHRNA1	100690
		cholinergic receptor, nicotinic, delta; CHRND	100720
		cholinergic receptor, nicotinic, epsilon; CHRNE	100725

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
MYASTHENIC SYNDROME, CONGENITAL, SLOW-CHANNEL; SCCMS	601462	CHOLINE ACETYLTRANSFERASE; CHAT	118490
		cholinergic receptor, nicotinic, alpha 1 (muscle); CHRNA1	100690
		cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) ; CHRNB1	100710
		cholinergic receptor, nicotinic, delta; CHRND	100720
		cholinergic receptor, nicotinic, epsilon; CHRNE	100725
MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF	545000	mitochondrially encoded tRNA lysine; MT-TK	590060
MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG	254800	CYSTATIN B (STEFIN B); CSTB	601145
NAIL-PATELLA SYNDROME; NPS	161200	LIM HOMEBOX TRANSCRIPTION FACTOR 1, BETA; LMX1B	602575
NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN	310468	CHLORIDE CHANNEL 5 (NEPHROLITHIASIS 2, X-LINKED, DENT DISEASE); CLCN5	300008
NEPHRONOPHTHISIS 1; NPHP1	256100	NEPHRONOPHTHISIS 1; NPHP1	256100
NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE; SRN1	600995	nephrosis 2, idiopathic, steroid-resistant (podocin); NPHS2	604766
NEUROFIBROMATOSIS, TYPE I; NF1	162200	NEUROFIBROMIN 1 (NEUROFIBROMATOSIS, VON RECKLINGHAUSEN DISEASE, WATSON DISEASE); NF1	162200
NEUROFIBROMATOSIS, TYPE II; NF2	101000	NEUROFIBROMIN 2 (BILATERAL ACOUSTIC NEUROMA); NF2	607379
NEUROLOGICAL DISORDERS		MITOCHONDRIAL GENOME	
		mitochondrially encoded ATP synthase 6; MT-ATP6	516060
		mitochondrially encoded tRNA leucine 1 (UUA/G); MT-TL1	590050
		mitochondrially encoded tRNA lysine; MT-TK	590060

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
NEUROMUSCULAR DISEASE		MITOCHONDRIAL GENOME	
		mitochondrially encoded ATP synthase 6; MT-ATP6	516060
		mitochondrially encoded tRNA leucine 1 (UUA/G); MT-TL1	590050
		mitochondrially encoded tRNA lysine; MT-TK	590060
NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA	551500	mitochondrially encoded ATP synthase 6; MT-ATP6	516060
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I; HSAN1	162400	SERINE PALMITOYLTRANSFERASE, LONG CHAIN BASE SUBUNIT 1; SPTLC1	605712
NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3	223900	INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B-CELLS, KINASE COMPLEX-ASSOCIATED PROTEIN; IKBKAP	603722
NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP	162500	PERIPHERAL MYELIN PROTEIN 22; PMP22	601097
NIEMANN-PICK DISEASE, TYPE C1; NPC1	257220	NIEMANN-PICK DISEASE, TYPE C1; NPC1	607623
NOONAN SYNDROME 1; NS1	163950	PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (NOONAN SYNDROME 1); PTPN11	176876
NORRIE DISEASE; NDP	310600	NORRIE DISEASE (PSEUDOGLIOMA); NDP	310600
OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD	164300	POLY(A) BINDING PROTEIN, NUCLEAR 1; PABPN1	602279
ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO	311250	ORNITHINE CARBAMOYLTRANSFERASE; OTC	300461
OSTEOGENESIS IMPERFECTA CONGENITA; OIC	166210	COLLAGEN, TYPE I, ALPHA 1; COL1A1	120150
		COLLAGEN, TYPE I, ALPHA 2; COL1A2	120160
OSTEOGENESIS IMPERFECTA, TYPE IV	166220	COLLAGEN, TYPE I, ALPHA 1; COL1A1	120150
		COLLAGEN, TYPE I, ALPHA 2; COL1A2	120160

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
OSTEOPETROSIS, AUTOSOMAL RECESSIVE	259700	T-cell, immune regulator 1, ATPase, H ⁺ transporting, lysosomal V0 subunit A3; TCIRG1	604592
OTOPALATODIGITAL SYNDROME, TYPE I; OPD1	311300	FILAMIN A, ALPHA (ACTIN BINDING PROTEIN 280); FLNA	300017
OTOPALATODIGITAL SYNDROME, TYPE II; OPD2	304120	FILAMIN A, ALPHA (ACTIN BINDING PROTEIN 280); FLNA	300017
PACHYONYCHIA CONGENITA, TYPE 1; PC1	167200	KERATIN 16 (FOCAL NON-EPIDERMOLYTIC PALMOPLANTAR KERATODERMA); KRT16	148067
		KERATIN 17; KRT17	148069
		KERATIN 6A; KRT6A	148041
		KERATIN 6B; KRT6B	148042
PACHYONYCHIA CONGENITA, TYPE 2; PC2	167210	KERATIN 16 (FOCAL NON-EPIDERMOLYTIC PALMOPLANTAR KERATODERMA); KRT16	148067
		KERATIN 17; KRT17	148069
		KERATIN 6A; KRT6A	148041
		KERATIN 6B; KRT6B	148042
PALLISTER-HALL SYNDROME; PHS	146510	GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome); GLI3	165240
PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK	144200	KERATIN 9 (EPIDERMOLYTIC PALMOPLANTAR KERATODERMA); KRT9	607606
PANCREATITIS, HEREDITARY; PCTT	167800	PROTEASE, SERINE, 1 (TRYPSIN 1); PRSS1	276000
PARAGANGLIOMAS 1; PGL1	168000	SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT D, INTEGRAL MEMBRANE PROTEIN; SDHD	602690
PARKINSON DISEASE, JUVENILE, AUTOSOMAL RECESSIVE; PJD	600116	Parkinson disease (autosomal recessive, juvenile) 2, parkin; PARK2	602544
PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS	309510	ARISTALESS RELATED HOMEBOX; ARX	300382
PEARSON MARROW-PANCREAS SYNDROME	557000	MITOCHONDRIAL GENOME	

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
PELIZAEUS-MERZBACHER DISEASE; PMD	312080	PELIZAEUS-MERZBACHER DISEASE; PMD	312080
PENDRED SYNDROME; PDS	274600	solute carrier family 26, member 4; SLC26A4	605646
PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY	601820	ATP-BINDING CASSETTE, SUB-FAMILY C (CFTR/MRP), MEMBER 8; ABCC8	600509
		POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 11; KCNJ11	600937
PEUTZ-JEGHERS SYNDROME; PJS	175200	serine/threonine kinase 11; STK11	602216
PFEIFFER SYNDROME	101600	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME); FGFR1	136350
		FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943
		FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
		TWIST HOMOLOG 1 (ACROCEPHALOSYNDACTYLY 3; SAETHRE-CHOTZEN SYNDROME) (DROSOPHILA); TWIST1	601622
PHENYLKETONURIA	261600	PHENYLALANINE HYDROXYLASE; PAH	261600
PHEOCHROMOCYTOMA	171300	SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT B, IRON SULFUR (IP); SDHB	185470
		SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT D, INTEGRAL MEMBRANE PROTEIN; SDHD	602690
PHOSPHATASE AND TENSIN HOMOLOG; PTEN	601728	PHOSPHATASE AND TENSIN HOMOLOG (MUTATED IN MULTIPLE ADVANCED CANCERS 1); PTEN	601728

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
PITUITARY DWARFISM III	262600	POU CLASS 1, HOMEODOMAIN 1; POU1F1	173110
		PROP PAIRED-LIKE HOMEODOMAIN 1; PROP1	601538
POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD	263200	POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1 (AUTOSOMAL RECESSIVE); PKHD1	606702
POLYCYSTIC KIDNEYS	173900	POLYCYSTIC KIDNEY DISEASE 1 (AUTOSOMAL DOMINANT); PKD1	601313
		POLYCYSTIC KIDNEY DISEASE 2 (AUTOSOMAL DOMINANT); PKD2	173910
POLYDACTYLY, PREAXIAL IV	174700	GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome); GLI3	165240
POLYPOSIS, JUVENILE INTESTINAL	174900	BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE IA; BMPR1A	601299
		MUTY HOMOLOG (E. COLI); MUTYH	604933
		SMAD family member 4; SMAD4	600993
POPLITEAL PTERYGIUM SYNDROME; PPS	119500	interferon regulatory factor 6; IRF6	607199
PORPHYRIA CUTANEA TARDA	176100	uroporphyrinogen decarboxylase; UROD	176100
PORPHYRIA VARIEGATA	176200	protoporphyrinogen oxidase; PPOX	600923
PORPHYRIA, ACUTE INTERMITTENT	176000	hydroxymethylbilane synthase; HMBS	176000
PORPHYRIA, CONGENITAL ERYTHROPOIETIC	263700	uroporphyrinogen III synthase (congenital erythropoietic porphyria); UROS	606938
POTASSIUM CHANNEL, VOLTAGE- GATED, ISK-RELATED SUBFAMILY, MEMBER 1; KCNE1	176261	POTASSIUM CHANNEL, VOLTAGE- GATED, ISK-RELATED SUBFAMILY, MEMBER 1; KCNE1	176261
POTASSIUM CHANNEL, VOLTAGE- GATED, ISK-RELATED SUBFAMILY, MEMBER 2; KCNE2	603796	POTASSIUM VOLTAGE-GATED CHANNEL, ISK-RELATED FAMILY, MEMBER 2; KCNE2	603796
POTASSIUM CHANNEL, VOLTAGE- GATED, SUBFAMILY H, MEMBER 2; KCNH2	152427	POTASSIUM VOLTAGE-GATED CHANNEL, SUBFAMILY H (EAG- RELATED), MEMBER 2; KCNH2	152427

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
PRADER-WILLI SYNDROME; PWS	176270	NECDIN HOMOLOG (MOUSE); NDN	602117
		SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE N; SNRPN	182279
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS	157640	mitochondrially encoded NADH dehydrogenase 5; MT-ND5	516005
		mitochondrially encoded NADH dehydrogenase 6; MT-ND6	516006
		POLYMERASE (DNA DIRECTED), GAMMA; POLG	174763
		PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 1; PEO1	606075
PROTEASE INHIBITOR 1; PI	107400	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1; SERPINA1	107400
PROTOPORPHYRIA, ERYTHROPOIETIC	177000	ferrochelatase (protoporphyrin); FECH	177000
PROXIMAL MYOPATHY WITH FOCAL DEPLETION OF MITOCHONDRIA	600706	MITOCHONDRIAL GENOME	
PSEUDOACHONDROPLASTIC DYSPLASIA; PSACH	177170	CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMP	600310
RENAL CELL CARCINOMA, PAPILLARY	605074	MET PROTO-ONCOGENE (HEPATOCTE GROWTH FACTOR RECEPTOR); MET	164860
RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT	179800	solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane protein band 3, Diego blood group); SLC4A1	109270
RETICULOSIS, FAMILIAL HISTIOCYTIC; FHL	267700	PERFORIN 1 (PORE FORMING PROTEIN); PRF1	170280
RETINITIS PIGMENTOSA 2, X-LINKED; RP2	312600	RETINITIS PIGMENTOSA GTPASE REGULATOR; RPGR	312610
RETINOBLASTOMA; RB1	180200	RETINOBLASTOMA 1 (INCLUDING OSTEOSARCOMA); RB1	180200
RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1	312700	RETINOSCHISIS (X-LINKED, JUVENILE) 1; RS1	312700

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
RETT SYNDROME; RTT	312750	METHYL CPG BINDING PROTEIN 2 (RETT SYNDROME); MECP2	300005
RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1	602771	SELENOPROTEIN N, 1; SEPN1	606210
ROBINOW SYNDROME, AUTOSOMAL RECESSIVE	268310	RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 2; ROR2	602337
SAETHRE-CHOTZEN SYNDROME; SCS	101400	TWIST HOMOLOG 1 (ACROCEPHALOSYNDACTYLY 3; SAETHRE-CHOTZEN SYNDROME) (DROSOPHILA); TWIST1	601622
SEGAWA SYNDROME, AUTOSOMAL RECESSIVE	605407	GTP CYCLOHYDROLASE 1 (DOPA-RESPONSIVE DYSTONIA); GCH1	600225
		TYROSINE HYDROXYLASE; TH	191290
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE	601457	RECOMBINATION ACTIVATING GENE 1; RAG1	179615
		RECOMBINATION ACTIVATING GENE 2; RAG2	179616
SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE	600802	JANUS KINASE 3 (A PROTEIN TYROSINE KINASE, LEUKOCYTE); JAK3	600173
SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1	300400	INTERLEUKIN 2 RECEPTOR, GAMMA (SEVERE COMBINED IMMUNODEFICIENCY); IL2RG	308380
SEX DETERMINATION		AMELOGENIN (AMELOGENESIS IMPERFECTA 1, X-LINKED); AMELX	300391
		AMELOGENIN, Y-LINKED; AMELY	410000
		SEX DETERMINING REGION Y; SRY	480000
SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS	182212	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (BACTERIA-EXPRESSED KINASE, KERATINOCYTE GROWTH FACTOR RECEPTOR, CRANIOFACIAL DYSOSTOSIS 1, CROUZON SYNDROME, PFEIFFER SYNDROME, JACKSON-WEISS SYNDROME); FGFR2	176943

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
SHWACHMAN-DIAMOND SYNDROME; SDS	260400	SHWACHMAN-BODIAN-DIAMOND SYNDROME; SBDS	607444
SICKLE CELL ANEMIA	603903	HEMOGLOBIN, BETA; HBB	141900
SILVER-RUSSELL SYNDROME; SRS	180860	SILVER-RUSSELL SYNDROME; SRS	180860
SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1	312870	GLYPICAN 3; GPC3	300037
SMITH-MAGENIS SYNDROME; SMS	182290	RETINOIC ACID INDUCED 1; RAI1	607642
SOLUTE CARRIER FAMILY 25 (CARNITINE/ACYLCARNITINE TRANSLOCASE), MEMBER 20; SLC25A20	212138	SOLUTE CARRIER FAMILY 25 (CARNITINE/ACYLCARNITINE TRANSLOCASE), MEMBER 20; SLC25A20	212138
SOTOS SYNDROME	117550	NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 1; NSD1	606681
SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4	182601	chromosome 1 open reading frame 2; C1orf2	604277
SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1	313200	ANDROGEN RECEPTOR (DIHYDROTESTOSTERONE RECEPTOR; TESTICULAR FEMINIZATION; SPINAL AND BULBAR MUSCULAR ATROPHY; KENNEDY DISEASE); AR	313700
SPINAL MUSCULAR ATROPHY WITH RESPIRATORY DISTRESS 1; SMARD1	604320	IMMUNOGLOBULIN MU BINDING PROTEIN 2; IGHMBP2	600502
SPINAL MUSCULAR ATROPHY, TYPE I; SMA1	253300	SURVIVAL OF MOTOR NEURON 1, TELOMERIC; SMN1	600354
SPINAL MUSCULAR ATROPHY, TYPE II; SMA2	253550	SURVIVAL OF MOTOR NEURON 1, TELOMERIC; SMN1	600354
SPINAL MUSCULAR ATROPHY, TYPE III; SMA3	253400	SURVIVAL OF MOTOR NEURON 1, TELOMERIC; SMN1	600354
SPINOCEREBELLAR ATAXIA 12; SCA12	604326	protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform; PPP2R2B	604325
SPINOCEREBELLAR ATAXIA 17; SCA17	607136	TATA BOX BINDING PROTEIN; TBP	600075
SPINOCEREBELLAR ATAXIA 1; SCA1	164400	ATAXIN 1; ATXN1	601556
SPINOCEREBELLAR ATAXIA 2; SCA2	183090	ATAXIN 2; ATXN2	601517
SPINOCEREBELLAR ATAXIA 6; SCA6	183086	CALCIUM CHANNEL, VOLTAGE-DEPENDENT, P/Q TYPE, ALPHA 1A SUBUNIT; CACNA1A	601011

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
SPINOCEREBELLAR ATAXIA 7; SCA7	164500	ATAXIN 7; ATXN7	607640
SPONDYLOCOSTAL DYSOSTOSIS, AUTOSOMAL RECESSIVE 1; SCDO1	277300	DELTA-LIKE 3 (DROSOPHILA); DLL3	602768
STICKLER SYNDROME, TYPE I; STL1	108300	COLLAGEN, TYPE II, ALPHA 1 (PRIMARY OSTEOARTHRITIS, SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL); COL2A1	120140
		COLLAGEN, TYPE XI, ALPHA 1; COL11A1	120280
		COLLAGEN, TYPE XI, ALPHA-2; COL11A2	120290
STICKLER SYNDROME, TYPE II; STL2	604841	COLLAGEN, TYPE II, ALPHA 1 (PRIMARY OSTEOARTHRITIS, SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL); COL2A1	120140
		COLLAGEN, TYPE XI, ALPHA 1; COL11A1	120280
		COLLAGEN, TYPE XI, ALPHA-2; COL11A2	120290
STICKLER SYNDROME, TYPE III; STL3	184840	COLLAGEN, TYPE II, ALPHA 1 (PRIMARY OSTEOARTHRITIS, SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL); COL2A1	120140
		COLLAGEN, TYPE XI, ALPHA 1; COL11A1	120280
		COLLAGEN, TYPE XI, ALPHA-2; COL11A2	120290
STREPTOMYCIN OTOTOXICITY	580000	mitochondrially encoded 12S RNA; MT-RNR1	561000
SURFACTANT, PULMONARY- ASSOCIATED PROTEIN B; SFTPB	178640	SURFACTANT, PULMONARY- ASSOCIATED PROTEIN B; SFTPB	178640
SYNDACTYLY, TYPE II	186000	homeobox D13; HOXD13	142989
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER; HHT	187300	ACTIVIN A RECEPTOR TYPE II- LIKE 1; ACVRL1	601284
		ENDOGLIN (OSLER-RENDU- WEBER SYNDROME 1); ENG	131195

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
THALASSEMIA	604131	HEMOGLOBIN, ALPHA 1; HBA1	141800
		HEMOGLOBIN, ALPHA 2; HBA2	141850
		HEMOGLOBIN, BETA; HBB	141900
		HEMOGLOBIN, DELTA; HBD	142000
THANATOPHORIC DYSPLASIA; TD	187600	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM); FGFR3	134934
THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR	188055	coagulation factor V (proaccelerin, labile factor); F5	227400
THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC	155240	ret proto-oncogene; RET	164761
TORSION DYSTONIA 1, AUTOSOMAL DOMINANT; DYT1	128100	TORSIN FAMILY 1, MEMBER A (TORSIN A); TOR1A	605204
TRANSTHYRETIN; TTR	176300	TRANSTHYRETIN (PREALBUMIN, AMYLOIDOSIS TYPE I); TTR	176300
TREACHER COLLINS-FRANCESCHETTI SYNDROME; TCOF	154500	Treacher Collins-Franceschetti syndrome 1; TCOF1	606847
TUBEROUS SCLEROSIS; TS	191100	TUBEROUS SCLEROSIS 1; TSC1	605284
		TUBEROUS SCLEROSIS 2; TSC2	191092
TURNERS SYNDROME		SEX DETERMINING REGION Y; SRY	480000
TYROSINEMIA, TYPE I	276700	FUMARYLACETOACETATE HYDROLASE (FUMARYLACETOACETASE); FAH	276700
ULLRICH CONGENITAL MUSCULAR DYSTROPHY	254090	COLLAGEN, TYPE VI, ALPHA 1; COL6A1	120220
		COLLAGEN, TYPE VI, ALPHA 2; COL6A2	120240
		COLLAGEN, TYPE VI, ALPHA 3; COL6A3	120250
UNIPARENTAL DISOMY CHROMOSOME 15		UNIPARENTAL DISOMY CHROMOSOME 15	
UNIPARENTAL DISOMY, CHROMOSOME 16		UNIPARENTAL DISOMY, CHROMOSOME 16	
UNIPARENTAL DISOMY, PATERNAL, CHROMOSOME 14	608149	UNIPARENTAL DISOMY, PATERNAL, CHROMOSOME 14	608149
VAN DER WOUDE SYNDROME; VWS	119300	interferon regulatory factor 6; IRF6	607199

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
VON HIPPEL-LINDAU SYNDROME; VHL	193300	VON HIPPEL-LINDAU SYNDROME; VHL	193300
WAGR SYNDROME	194072	PAIRED BOX 6; PAX6	607108
WILMS TUMOR 1; WT1	194070	WILMS TUMOR 1; WT1	607102
WILMS TUMOR AND PSEUDOHERMAPHRODITISM	194080	WILMS TUMOR 1; WT1	607102
WILSON DISEASE	277900	ATPase, Cu ⁺⁺ transporting, beta polypeptide; ATP7B	606882
WISKOTT-ALDRICH SYNDROME; WAS	301000	WISKOTT-ALDRICH SYNDROME (ECZEMA-THROMBOCYTOPENIA); WAS	300392
WITKOP SYNDROME	189500	msh homeobox 1; MSX1	142983
WOLFRAM SYNDROME	222300	WOLFRAM SYNDROME 1 (WOLFRAMIN); WFS1	606201
X LINKED DISEASE		LABORATORY SPECIFIC TEST	
Y CHROMOSOME MICRODELETIONS		LABORATORY SPECIFIC TEST	
ZYGOSITY ANALYSIS		LABORATORY SPECIFIC TEST	

Section 2

New tests that have been evaluated through the UKGTN Gene Dossier process, have been accepted by GenCAG and are currently being set up as NHS service

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
AICARDI-GOUTIERES SYNDROME 1; AGS1	225750	3-PRIME @REPAIR EXONUCLEASE 1; TREX1	606609
AICARDI-GOUTIERES SYNDROME 2; AGS2	610181	RIBONUCLEASE H2, SUBUNIT B; RNASEH2B	610326
AICARDI-GOUTIERES SYNDROME 3; AGS3	610329	RIBONUCLEASE H2, SUBUNIT C; RNASEH2C	610330
AICARDI-GOUTIERES SYNDROME 4; AGS4	610333	RIBONUCLEASE H2, SUBUNIT A; RNASEH2A	606034
AICARDI-GOUTIERES SYNDROME 5; AGS5	610905	3-PRIME @REPAIR EXONUCLEASE 1; TREX1	606609
CEREBRAL CAVERNOUS MALFORMATIONS; CCM	116860	KRIT1, ankyrin repeat containing; KRIT1	604214
		cerebral cavernous malformation 2; CCM2	603284
		programmed cell death 10; PDCD10	603285
Charcot Marie Tooth disease, demyelinating, type 1D; CMT1D	607678	early growth response 2 (Krox-20 homolog, Drosophila); EGR2	129010
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2	609260	MITOFUSIN 2; MFN2	608507
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E	607684	NEUROFILAMENT, LIGHT POLYPEPTIDE 68KDA; NEFL	162280
CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K	607831	GANGLIOSIDE-INDUCED DIFFERENTIATION-ASSOCIATED PROTEIN 1; GDAP1	606598
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F	607734	NEUROFILAMENT, LIGHT POLYPEPTIDE 68KDA; NEFL	162280
CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A	214400	GANGLIOSIDE-INDUCED DIFFERENTIATION-ASSOCIATED PROTEIN 1; GDAP1	606598
Charge Syndrome	214800	Chromodomain helicase DNA-binding protein-7; CHD7	608892
EPISODIC ATAXIA, TYPE 2; EA2	108500	CALCIUM CHANNEL, VOLTAGE-DEPENDENT, P/Q TYPE, ALPHA 1A SUBUNIT; CACNA1A	601011
Fibrodysplasia Ossificans Progressiva; FOP	135100	Activin A, type 1 receptor ; ACVR1	102576

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
Hypertrophic Neuropathy of Dejerine Sottas	145900	early growth response 2 (Krox-20 homolog, Drosophila); EGR2	129010
		PERIAXIN; PRX	605725
INFANTILE SPASM SYNDROME, X-LINKED	308350	CYCLIN-DEPENDENT KINASE-LIKE 5; CDKL5	300203
MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1	141500	CALCIUM CHANNEL, VOLTAGE-DEPENDENT, P/Q TYPE, ALPHA 1A SUBUNIT; CACNA1A	601011
NEUROPATHY, CONGENITAL HYPOMYELINATING	605253	early growth response 2 (Krox-20 homolog, Drosophila); EGR2	129010
OSTEOGENESIS IMPERFECTA TYPE 3; OI3	259420	collagen, type I, alpha 1; COL1A1	120150
		collagen, type I, alpha 2; COL1A2	120160
RETINITIS PIGMENTOSA; RP	268000	retinitis pigmentosa GTPase regulator; RPGR	312610
		retinitis pigmentosa 2 (X-linked recessive); RP2	312600
		rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4, autosomal dominant); RHO	180380
		peripherin 2 (retinal degeneration, slow); PRPH2	179605
		PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae); PRPF31	606419
		PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae); PRPF8	607300
		neural retina leucine zipper; NRL	162080
		MP (inosine monophosphate) dehydrogenase 1; IMPDH1	146690
		PDGFA associated protein 1; PDAP1	607075
		retinitis pigmentosa 1 (autosomal dominant); RP1	603937
SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A	182600	SPASTIC PARAPLEGIA 3A (AUTOSOMAL DOMINANT); SPG3A	606439
Spastic Paraplegia 31, autosomal dominant; SPG31	610250	RECEPTOR ACCESSORY PROTEIN 1; REEP1	609139

Section 3

Approved tests that are currently not available from any UKGTN laboratories

DISEASE		GENE	
NAME	OMIM	NAME	OMIM
JERVELL AND LANGE-NIELSEN SYNDROME; JLNS1	220400	POTASSIUM VOLTAGE-GATED CHANNEL, ISK-RELATED FAMILY, MEMBER 1; KCNE1	176261
MICROCEPHALY, PRIMARY AUTOSOMAL RECESSIVE, 1; MCPH1	251200	ASP (ABNORMAL SPINDLE)-LIKE, MICROCEPHALY ASSOCIATED (DROSOPHILA); ASPM	605481
		CDK5 REGULATORY SUBUNIT ASSOCIATED PROTEIN 2; CDK5RAP2	608201
		centromere protein J; CENPJ	609279

UKGTN
c/o Specialised Services
Bexley Care Trust
221 Erith Road
Bexleyheath
Kent
DA7 6HZ

email: ukgtn@bexley.nhs.uk

telephone: 020 8298 6111

website: www.ukgtn.nhs.uk